Click Here to return To Results

 

Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder NEJM 381:614-625, Pittock, S.J.,et al, 2019 See this aricle in Pubmed Article Abstract Among patients with AQP4-IgG-positive NMOSD, those who received eculizumab had a significantly lower risk of relapse than those who received placebo. There was no significant between-group difference in measures of disability progression.

Related Tags

(click to filter results - removes previous filter) eculizumab monoclonal antibodies neuromyelitis optica (Devic's disease) neuromyelitis optica spectrum disorder treatment of neurologic disorder water channel antibodies

Click Here to return To Results